856978-80-8

Usage

Type of drug

Synthetic opioid analgesic

Origin

Derived from the medication tramadol

Mechanism of action

Acts as a central nervous system depressant, binding to opioid receptors in the brain and spinal cord to produce pain relief and sedation

Medical use

Used to treat moderate to severe pain

Potential for abuse

Known for its potential for abuse and dependence

Legal status

Classified as a Schedule II controlled substance in the United States due to its high potential for abuse and addiction

Side effects

May cause respiratory depression and overdose, and long-term use can lead to physical and psychological dependence

Precautions

Should be used with caution and under the supervision of a qualified healthcare professional
It's important to note that while O-Desmethyltramadol can be effective in treating moderate to severe pain, it also carries significant risks and potential for abuse and addiction. As with all medications, it should be used responsibly and under the guidance of a qualified healthcare professional.

Upstream product

• 754145-88-5 C₁₁H₁₅NO₂ 
• 123-11-5 4-methoxy-benzaldehyde 
• 78-96-6 3-amino-2-propanol 

Downstream Products

• 854304-10-2 2-chloro-N-(4-methoxybenzyl)propan-1-amine 
• 1616238-98-2 (2R,3R)-2,3-diacetoxy-4-((2-chloropropyl)(4-methoxybenzyl)amino)-4-oxobutanoic acid 
• 1616238-99-3 (2R,3R)-1-(tert-butoxy)-4-((2-chloropropyl)(4-methoxybenzyl)amino)-1,4-dioxobutane-2,3-diyl diacetate 
• 1616239-00-9 (2R,3R)-tert-butyl 4-((2-chloropropyl)(4-methoxybenzyl)amino)-2,3-dihydroxy-4-oxobutanoate 
• 1616239-01-0 (R)-tert-butyl 2-hydroxy-2-((2S,6S)-4-(4-methoxybenzyl)-6-methyl-3-oxomorpholin-2-yl)acetate 
• 1616239-02-1 (R)-tert-butyl 2-hydroxy-2-((2R,6R)-4-(4-methoxybenzyl)-6-methyl-3-oxomorpholin-2-yl)acetate 
• 1375744-68-5 3-acetyl-4-[(4-methoxyphenyl)methyl]-1-methylpiperazine-2,5-dione 
• 1375744-69-6 phenyl N-({[(4-methoxyphenyl)methyl](2-oxopropyl)carbamoyl}methyl)-N-methylcarbamate 
• 1375744-89-0 phenyl N-{[(2-hydroxypropyl)[(4-methoxyphenyl)methyl]carbamoyl]methyl}-N-methylcarbamate 

Relevant academic research and scientific papers

FACTOR IXA INHIBITORS

The present invention provides a compound of Formula (I) (structurally represented) wherein R1, R2, R3 and R4 are independently H or C1-6 alkyl, provided that when R1, R2, and R3 are H, R4 is C1-6 alkyl, and when R1, R2, and R4 are H, R3 is C1-6 alkyl, and when R1, R3, and R4 are H, R2 is C1-6 alkyl, and when R2, R3, and R4 are H, R1 is C1-6 alkyl; and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes.

FACTOR IXA INHIBITORS

The present invention provides a compound of Formula (I) (structurally represented) wherein R1 is H or C1-6 alkyl, R2 is H or C1-6 alkyl or CH20H, R3 is H or C1-6 alkyl, and R4 is H or C1-6 alkyl, provided that when R1, R2, and R3 are H, R4 is C1-6 alkyl, and when R1, R2, and R4 are H, then R3 is C1-6 alkyl, and when R1, R3, and R4 are H, R2 is C1-6 alkyl or-CH20H, and when R2, R3, and R4 are H, then R1 is C 1-6 alkyl; A is 1 ) a 9-10 membered bicyclic heterocycle having 1-3 heteroatoms independently selected from N, S and 0, which 9-10 membered bicyclic heterocycle is unsubstituted or substituted with R5 and unsubstituted or substituted with R6 and unsubstituted or substituted with NH2, or 2) a 6-9 membered monocyclic or bicyclic carbocyclic ring system unsubstituted or substituted with R5, unsubstituted or substituted with R6, and unsubstituted or substituted with -CH2NH2; and B is 1) a 5- or 6-membered monocyclic heterocycle having 1 or 2 heteroatoms independently selected from N, S or 0, which is unsubstituted or substituted on a carbon or nitrogen atom with R7, unsubstituted or substituted on a carbon or nitrogen atom with R8, and unsubstituted or substituted on a carbon or nitrogen atom with R9, or 2) an 8- or 9-membered fused bicyclic heterocycle having 1, 2 or 3 nitrogen atoms which is unsubstituted or substituted on a carbon or nitrogen atom with R7, and unsubstituted or substituted on a carbon or nitrogen atom with R8; and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses.

A Dieckmann cyclization route to piperazine-2,5-diones

Piperazine-2,5-diones are formed by Dieckmann cyclization (NaH, THF) of substructures of the type CH2-N(R)C(O)CH2N(R′) CO2Ph in which the terminal methylene (CH2) that is adjacent to nitrogen closes onto the carbonyl group of the phenyl carbamate unit at the other end of the chain. R and R′ are alkyl groups, and the terminal methylene is activated by a ketone carbonyl, a nitrile, an ester, or a phosphoryl group. The starting materials are assembled by standard acylation and oxidation processes, starting from a β-(alkylamino)alcohol, an (alkylamino)acetonitrile, an (alkylamino) ester, or an (alkylamino)methyl phosphonate.